Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): The phase 3 KEYNOTE-689 study Meeting Abstract
| Authors: | Uppaluri, R.; Lee, N.; Westra, W.; Cohen, E.; Haddad, R.; Temam, S.; Le Tourneau, C.; Chernock, R.; Safina, S.; Klochikhin, A.; Meirovitz, A.; Brana, I.; Ge, J. Y.; Swaby, R.; Pinheiro, C.; Adkins, D. |
| Abstract Title: | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): The phase 3 KEYNOTE-689 study |
| Meeting Title: | 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 7 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Nov 6-10 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2019-11-01 |
| Start Page: | 282 |
| Language: | English |
| ACCESSION: | WOS:000496473200821 |
| PROVIDER: | wos |
| PMCID: | PMC6833189 |
| PUBMED: | 31694725 |
| DOI: | 10.1186/s40425-019-0763-1 |
| Notes: | Meeting Abstract: P401 -- Source: Wos |
